Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more
Market Cap & Net Worth: Valbiotis SAS (ALVAL)
Valbiotis SAS (PA:ALVAL) has a market capitalization of $23.92 Million (€23.30 Million) as of March 19, 2026. Listed on the PA stock exchange, this France-based company holds position #24821 globally and #223 in its home market, demonstrating a -0.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Valbiotis SAS's stock price €0.99 by its total outstanding shares 23657340 (23.66 Million).
Valbiotis SAS Market Cap History: 2017 to 2026
Valbiotis SAS's market capitalization history from 2017 to 2026. Data shows change from $154.03 Million to $23.92 Million (-23.12% CAGR).
Valbiotis SAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Valbiotis SAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
210.92x
Valbiotis SAS's market cap is 210.92 times its annual revenue
0.14x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $154.03 Million | $3.00K | -$2.44 Million | 51342.84x | N/A |
| 2018 | $78.46 Million | $79.00K | -$4.97 Million | 993.14x | N/A |
| 2019 | $54.40 Million | $91.00K | -$5.50 Million | 597.75x | N/A |
| 2020 | $147.16 Million | $3.09 Million | -$3.83 Million | 47.59x | N/A |
| 2021 | $166.34 Million | $298.00K | -$8.68 Million | 558.20x | N/A |
| 2022 | $87.42 Million | $785.00K | -$12.31 Million | 111.36x | N/A |
| 2023 | $121.42 Million | $4.73 Million | -$7.37 Million | 25.65x | N/A |
| 2024 | $36.91 Million | $175.00K | -$10.03 Million | 210.92x | N/A |
Competitor Companies of ALVAL by Market Capitalization
Companies near Valbiotis SAS in the global market cap rankings as of March 19, 2026.
Key companies related to Valbiotis SAS by market ranking:
- Nestle SA (PINK:NSRGF): Ranked #55 globally with a market cap of $258.19 Billion USD.
- Nestlé S.A. (SW:NESN): Ranked #68 globally with a market cap of $226.90 Billion USD ( CHF207.77 Billion CHF).
- Danone S.A (OTCQX:GPDNF): Ranked #437 globally with a market cap of $49.73 Billion USD.
- Danone SA (PA:BN): Ranked #458 globally with a market cap of $47.46 Billion USD ( €46.23 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #55 | Nestle SA | PINK:NSRGF | $258.19 Billion | $100.43 |
| #68 | Nestlé S.A. | SW:NESN | $226.90 Billion | CHF80.84 |
| #437 | Danone S.A | OTCQX:GPDNF | $49.73 Billion | $78.67 |
| #458 | Danone SA | PA:BN | $47.46 Billion | €73.12 |
Valbiotis SAS Historical Marketcap From 2017 to 2026
Between 2017 and today, Valbiotis SAS's market cap moved from $154.03 Million to $ 23.92 Million, with a yearly change of -23.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €23.92 Million | +41.93% |
| 2025 | €16.85 Million | -54.34% |
| 2024 | €36.91 Million | -69.60% |
| 2023 | €121.42 Million | +38.89% |
| 2022 | €87.42 Million | -47.45% |
| 2021 | €166.34 Million | +13.04% |
| 2020 | €147.16 Million | +170.54% |
| 2019 | €54.40 Million | -30.67% |
| 2018 | €78.46 Million | -49.06% |
| 2017 | €154.03 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Valbiotis SAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.92 Million USD |
| MoneyControl | $23.92 Million USD |
| MarketWatch | $23.92 Million USD |
| marketcap.company | $23.92 Million USD |
| Reuters | $23.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.